Laurus Labs Ltd
LAURUSLABSLaurus Labs Ltd
LAURUSLABS


Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
161.83 | 7.87 | 0.13% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
48.59 | 6.21 | 0.55% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Investor Presentation
View olderÂPeers
Compare with peersÂGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,781.94 | 1,937.03 | 2,085.36 | 2,308.07 | 2,837.64 | 4,837.17 | 4,950.87 | 6,046.55 | 5,067.17 | 5,308.39 | ||||||||||
Raw Materials | 1,033.24 | 1,031.67 | 1,088.41 | 1,267.63 | 1,629.55 | 2,455.20 | 2,414.94 | 2,752.28 | 2,533.30 | 4,397.16 | ||||||||||
Power & Fuel Cost | 57.96 | 66.27 | 94.21 | 109.37 | 136.77 | 157.75 | 204.47 | 324.10 | 338.15 | |||||||||||
Employee Cost | 175.46 | 204.73 | 238.14 | 276.33 | 320.77 | 397.04 | 469.55 | 557.43 | 614.85 | |||||||||||
Selling & Administrative Expenses | 67.97 | 92.25 | 96.07 | 140.99 | 189.38 | 239.88 | 276.15 | 291.01 | 335.07 | |||||||||||
Operating & Other expenses | 80.75 | 102.10 | 126.03 | 141.61 | -9.30 | 12.96 | 148.03 | 523.54 | 441.96 | |||||||||||
EBITDA | 366.56 | 440.01 | 442.50 | 372.14 | 570.47 | 1,574.34 | 1,437.73 | 1,598.19 | 803.84 | 911.23 | ||||||||||
Depreciation/Amortization | 86.41 | 105.98 | 125.45 | 164.19 | 187.27 | 205.07 | 251.49 | 324.08 | 384.58 | 421.91 | ||||||||||
PBIT | 280.15 | 334.03 | 317.05 | 207.95 | 383.20 | 1,369.27 | 1,186.24 | 1,274.11 | 419.26 | 489.32 | ||||||||||
Interest & Other Items | 111.11 | 99.90 | 79.64 | 88.19 | 89.59 | 68.16 | 102.39 | 165.17 | 182.90 | 210.10 | ||||||||||
PBT | 169.04 | 234.13 | 237.41 | 119.76 | 293.61 | 1,301.11 | 1,083.85 | 1,108.94 | 236.36 | 279.22 | ||||||||||
Taxes & Other Items | 35.30 | 43.86 | 69.81 | 25.99 | 38.34 | 317.53 | 256.33 | 318.83 | 75.81 | 78.96 | ||||||||||
Net Income | 133.74 | 190.27 | 167.60 | 93.77 | 255.27 | 983.58 | 827.52 | 790.11 | 160.55 | 200.26 | ||||||||||
EPS | 0.86 | 1.81 | 3.17 | 1.77 | 4.79 | 18.36 | 15.41 | 14.69 | 2.98 | 3.72 | ||||||||||
DPS | 0.10 | 0.30 | 0.30 | 0.30 | 0.50 | 2.00 | 2.00 | 2.00 | 0.80 | 0.80 | ||||||||||
Payout ratio | 0.12 | 0.17 | 0.09 | 0.17 | 0.10 | 0.11 | 0.13 | 0.14 | 0.27 | 0.22 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Laurus Labs Ltd | 201.86 | 7.87 | 0.13% |
Sun Pharmaceutical Industries Ltd | 43.75 | 6.24 | 0.77% |
Cipla Ltd | 28.85 | 4.44 | 0.88% |
Torrent Pharmaceuticals Ltd | 62.82 | 15.18 | 0.91% |
Price Comparison
Compare LAURUSLABS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Laurus Labs Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0092% | Percentage of the fund’s portfolio invested in the stock 1.14% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/85 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4416% | Percentage of the fund’s portfolio invested in the stock 0.68% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 54/77 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4269% | Percentage of the fund’s portfolio invested in the stock 0.87% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 43/68 (+5) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
LAURUSLABS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.33 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 6, 2024
Dividend/Share
₹0.40
Ex DateEx Date
Nov 6, 2024
Cash Dividend
Ex DateEx DateMay 8, 2024
Dividend/Share
₹0.40
Ex DateEx Date
May 8, 2024
Cash Dividend
Ex DateEx DateNov 2, 2023
Dividend/Share
₹0.40
Ex DateEx Date
Nov 2, 2023
Cash Dividend
Ex DateEx DateMay 10, 2023
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2023
Cash Dividend
Ex DateEx DateNov 3, 2022
Dividend/Share
₹0.80
Ex DateEx Date
Nov 3, 2022
Laurus Labs Ltd is down for a fifth straight session today. The stock is quoting at Rs 546.75, down 9.03% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.87% on the day, quoting at 22830.85. The Sensex is at 75660.79, down 0.63%.Laurus Labs Ltd has lost around 1.82% in last one month.Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has eased around 5.47% in last one month and is currently quoting at 21427.1, down 3.06% on the day. The volume in the stock stood at 48.57 lakh shares today, compared to the daily average of 44.71 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 546.25, down 9.02% on the day. Laurus Labs Ltd jumped 39.28% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.The PE of the stock is 129.77 based on TTM earnings ending December 24.Powered by Capital Market - Live
Laurus Labs Ltd is up for a third straight session today. The stock is quoting at Rs 638.45, up 1.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.41% on the day, quoting at 23600.05. The Sensex is at 77920.62, down 0.45%. Laurus Labs Ltd has gained around 4.25% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 18.29 lakh shares today, compared to the daily average of 42.52 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 639.8, up 1.03% on the day. Laurus Labs Ltd is up 60.15% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 136.31 based on TTM earnings ending December 24.Powered by Capital Market - Live
Net profit of Laurus Labs rose 298.88% to Rs 92.30 crore in the quarter ended December 2024 as against Rs 23.14 crore during the previous quarter ended December 2023. Sales rose 18.42% to Rs 1415.05 crore in the quarter ended December 2024 as against Rs 1194.92 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1415.051194.92 18 OPM %20.1515.18 - PBDT236.77133.03 78 PBT130.6834.62 277 NP92.3023.14 299 Powered by Capital Market - Live
Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 585.45, up 3.11% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.64% on the day, quoting at 23350.8. The Sensex is at 77182.56, up 0.74%. Laurus Labs Ltd has added around 3.42% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 1.96% in last one month and is currently quoting at 22061.7, up 0.31% on the day. The volume in the stock stood at 9.9 lakh shares today, compared to the daily average of 18.42 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 585.1, up 2.72% on the day. Laurus Labs Ltd is up 46.75% in last one year as compared to a 9.94% gain in NIFTY and a 26.31% gain in the Nifty Pharma index.The PE of the stock is 130.29 based on TTM earnings ending September 24.Powered by Capital Market - Live
Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
Laurus Labs Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 590.25, up 0.61% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.03% on the day, quoting at 23805.25. The Sensex is at 78760.73, up 0.08%. Laurus Labs Ltd has added around 2.33% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 3.28% in last one month and is currently quoting at 23008.35, up 0.77% on the day. The volume in the stock stood at 16.64 lakh shares today, compared to the daily average of 19.78 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 593.15, up 0.61% on the day. Laurus Labs Ltd is up 36.3% in last one year as compared to a 9.49% gain in NIFTY and a 37.53% gain in the Nifty Pharma index.The PE of the stock is 134.5 based on TTM earnings ending September 24.Powered by Capital Market - Live
Additionally, Laurus Labs will co-invest Rs 40 crore at the same valuation. The promoters of Laurus Bio have been issued share warrants, exercisable within two years from the date of issue at the same valuation. Laurus Labs and Eight Roads Ventures have the right to invest up to an additional Rs 35 crore before December 2025 at the same valuation. Upon completion of the transaction, Laurus Labs, Eight Roads Ventures, and the promoters of Laurus Bio will hold 75%, 14%, and 9% stakes, respectively, on a fully diluted basis. The company will use the equity infusion to expand its fermentation-based manufacturing capabilities to meet growing customer demand. Satyanarayana Chava, founder & CEO of Laurus Labs, and Rajesh Krishnamurthy, CEO of Laurus Bio, commented, 'We are pleased to announce rejoining the partnership with Eight Roads Ventures and Laurus Lab's continued commitment with an additional investment into Laurus Bio. The company, promoters of Laurus Bio, Eight Roads Ventures, and F-Prime Capital will drive expansion of the manufacturing and R&D infrastructure to further accelerate growth opportunities. Eight Roads Ventures brings a global network, relevant industry experience, and a strong track record of biopharmaceuticals and CDMO investing. This investment will enable the company to further expand and accelerate microbial-fermentation capabilities, including faster development of new products, speed-up internal pipeline, enhancing high-quality commercial-scale capacity to partners, and growing our industry position.' Prem Pavoor, Managing Partner, Eight Roads Ventures India, said, 'We are thrilled to re-unite with two of our former partners, Laurus Labs & Laurus Bio, who have built a best-in-class biomanufacturing platform to cater to the growing global demand for sustainable manufacturing technologies. Biomanufacturing is already being utilized across a range of industries, including personal care, materials, food and nutrition, and pharmaceuticals. We are looking forward to growing Laurus Bio into a global leader in this emerging segment.' Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro, and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations and provides contract research and manufacturing services (CRAMS) to global pharma companies. The company's consolidated net profit tumbled 46.35% to Rs 19.84 crore in Q2 FY25 as against Rs 36.95 crore posted in Q2 FY24. Net sales marginally declined to Rs 1,223.70 crore in Q2 FY25 from Rs 1,224.45 crore reported in Q2 FY24. Shares of JSW Energy rose 0.25% to close at Rs 589.60 on Friday, 6 December 2024.Powered by Capital Market - Live
Laurus Labs announced that its subsidiary, Laurus Bio, has signed a definitive agreement for an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs also agreed to co-invest an additional Rs 40 crore at the same valuation. The Promoters of Laurus Bio have also been issued share warrants, exercisable up to two years from the date of issue at the same valuation. Laurus Labs or Eight Roads Ventures have the right to invest up to an additional amount of Rs 35 crore before Dec 2025 at the same valuation. Upon completion of the transaction, the Company, Eight Roads Ventures and the Promoters of Laurus Bio will hold 75%, 14% and 9% stake respectively on a fully diluted basis. The Company will utilize the equity infusion for further expansion of its fermentation-based manufacturing capabilities in order to cater to growing customer demand. Powered by Capital Market - Live
Laurus Labs Ltd gained for a fifth straight session today. The stock is quoting at Rs 582.25, up 0.27% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 24439.9. The Sensex is at 80883.01, up 0.05%. Laurus Labs Ltd has gained around 19.01% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 1.21% in last one month and is currently quoting at 22445.7, down 0.26% on the day. The volume in the stock stood at 14.43 lakh shares today, compared to the daily average of 27.76 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 582, down 0.06% on the day. Laurus Labs Ltd is up 54.71% in last one year as compared to a 17.19% jump in NIFTY and a 37.94% jump in the Nifty Pharma index.The PE of the stock is 133.14 based on TTM earnings ending September 24.Powered by Capital Market - Live
Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 577.25, up 1.78% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Laurus Labs Ltd has added around 18.42% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 29.18 lakh shares today, compared to the daily average of 27.12 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 580.3, up 1.89% on the day. Laurus Labs Ltd is up 52.21% in last one year as compared to a 16.91% gain in NIFTY and a 38.53% gain in the Nifty Pharma index.The PE of the stock is 129.98 based on TTM earnings ending September 24.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.03%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 1.05% to 1.34%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.35%, vs industry avg of 15.28%